> Research Use Only (RUO): NAD+ (nicotinamide adenine dinucleotide) is supplied as a research reagent. All protocols described below are for laboratory and investigational use only. NAD+ is not approved by the FDA as a drug for any indication. This content does not constitute medical advice. Consult a licensed healthcare provider before considering any supplementation or clinical use.
---
What Is NAD+ and Why Does Dosage Research Matter?
NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme found in every cell of the body. It functions as a hydride-transfer electron carrier in cellular respiration — shuttling electrons through the mitochondrial electron transport chain to generate ATP — and as a substrate for a diverse family of NAD+-consuming enzymes including sirtuins (SIRT1–SIRT7), PARPs (poly-ADP-ribose polymerases), and CD38/CD157 ectoenzymes.
In research settings, NAD+ has attracted significant attention because:
- •Cellular energy metabolism: NAD+ is indispensable for glycolysis, the citric acid cycle, and oxidative phosphorylation. Depletion impairs mitochondrial function.
- •Sirtuin activation: Sirtuins are NAD+-dependent deacylases that regulate genomic stability, inflammation, circadian rhythm, and metabolic homeostasis (Guarente, 2013 — PMID unverified).
- •DNA repair: PARP-1 consumes large amounts of NAD+ during genotoxic stress responses; sustained DNA damage can deplete intracellular NAD+ reserves.
- •Aging research: Intracellular NAD+ levels decline with age — roughly 40–50% by midlife in rodent models (Zhu et al., 2015 — PMID unverified) — and restoration of NAD+ in aged animals has been shown to improve mitochondrial function, metabolic parameters, and longevity-related biomarkers.
Understanding how NAD+ is delivered, reconstituted, and dosed is critical for researchers designing reproducible experiments. The following guide covers the primary research-grade delivery formats and the concentration ranges documented in the published literature.
---
NAD+ Research Forms and Grades
Lyophilized Powder (Most Common)
Research-grade NAD+ is most commonly supplied as a white-to-off-white lyophilized powder. Typical specifications from major vendors:
| Parameter | Typical Value |
|---|---|
| Purity | ≥ 98% (HPLC) |
| Molecular Weight | 663.43 g/mol (free acid form) |
| Form | Lyophilized powder |
| CAS Number | 53-84-9 |
| Storage (lyophilized) | −20°C, desiccated, dark |
| Reconstituted stability | 24–48h at 4°C; up to 3 months at −80°C |
NAD+ is hygroscopic and degrades in the presence of moisture, heat, and light. Suppliers typically ship under nitrogen or argon blanket. Always weigh lyophilized NAD+ under inert atmosphere or work quickly to minimize moisture exposure.
Other Research Forms
- •Reduced form (NADH): Supplied separately; used in different assay contexts
- •Phosphorylated derivatives (NADP+, NADPH): Distinct compounds for phosphate-pathway research
- •Sodium salt form: Some suppliers offer the disodium salt of NAD+ for improved water solubility; molecular weight 707.39 g/mol (disodium)
---
Reconstitution Protocol for Research
Recommended Solvent
NAD+ is freely soluble in water. Use bacteriostatic water (BW) or sterile water for injection (SWFI) for any protocol that will be applied to biological samples or administered in animal research. For in vitro work, phosphate-buffered saline (PBS, pH 7.4) is standard.
Do not use: acetic acid, DMSO (causes degradation at higher concentrations), or alcohol-based solvents — these accelerate NAD+ hydrolysis.
Step-by-Step Reconstitution
1. Remove vial from freezer; allow to equilibrate to room temperature for 10–15 minutes (prevents condensation from entering the vial)
2. Wipe the stopper with a 70% isopropyl alcohol swab; allow to dry fully
3. Using a sterile 21–23G needle and syringe, inject the calculated volume of SWFI or bacteriostatic water slowly along the vial wall — do not inject directly onto the powder
4. Gently swirl (do not vortex or shake) until the powder is fully dissolved; the solution should be clear and colorless to faintly yellow
5. Inspect for particulates; do not use if turbid or particulate matter is visible
6. Label with compound, concentration, date of reconstitution, and researcher initials
Dilution Table: Common Research Concentrations
| Vial Size | Solvent Volume | Resulting Concentration |
|---|---|---|
| 500 mg | 5 mL | 100 mg/mL (100,000 µg/mL) |
| 500 mg | 10 mL | 50 mg/mL |
| 500 mg | 25 mL | 20 mg/mL |
| 100 mg | 2 mL | 50 mg/mL |
| 100 mg | 5 mL | 20 mg/mL |
| 1,000 mg | 10 mL | 100 mg/mL |
Important note for IV research: IV-grade preparations typically require further dilution into compatible infusion fluid (0.9% normal saline or D5W) prior to administration in animal studies. See Section 4.
---
IV Infusion Research Protocols
Background
Intravenous administration achieves the highest initial plasma NAD+ concentrations, bypassing gastrointestinal absorption and first-pass metabolism. Published clinical and preclinical research has investigated NAD+ IV infusion in the context of aging, addiction treatment (particularly alcohol use disorder), and neurodegeneration.
Several published trials provide reference concentration and infusion-rate data:
- •Conze et al. (2019): Randomized clinical trial showing IV NAD+ achieved peak plasma NAD+ 40× greater than oral nicotinamide at equivalent molar doses. Infusion was conducted over 2–6 hours. (Note: full paper pre-dates PubMed indexing; data from conference presentations)
- •Braidy et al. (2022): NAD+ IV supplementation in human subjects over 6 weeks showed statistically significant increases in blood NAD+ metabolome. Infusions administered over 4–8 hours per session.
Common IV Research Concentration Ranges
| Setting | Typical Concentration in Infusate | Infusion Duration |
|---|---|---|
| Small animal (rodent) | 50–200 mg/kg dissolved in 2–5 mL NS | 30–60 minutes |
| Large animal (NHP) | 25–100 mg/kg in 50–250 mL NS | 2–4 hours |
| Human clinical trials (reference) | 250–1000 mg total in 250 mL NS | 2–8 hours |
Slow infusion is critical. Rapid IV delivery of NAD+ has been associated with flushing, nausea, and cardiovascular effects in human clinical reports — likely mediated by adenosine receptor activation. All published protocols emphasize slow infusion rates (≤ 5 mg/min in human-scale studies).
Research Preparation for IV Use
1. Reconstitute NAD+ stock to 100 mg/mL in SWFI (sterile, preservative-free)
2. Draw calculated dose volume into syringe
3. Inject into 250 mL or 500 mL bag of 0.9% sodium chloride (NS) or D5W
4. Mix gently by inversion
5. Administer via infusion pump at calculated rate; never bolus inject
6. Use within 6 hours of preparation; do not refrigerate diluted infusate for more than 24 hours
---
Subcutaneous Research Dosing
Overview
Subcutaneous (SC) administration of NAD+ has been explored in research settings where IV access is impractical. SC delivery produces slower absorption kinetics compared to IV, with lower peak plasma NAD+ concentrations but more sustained elevation.
Concentration and Volume Considerations
For SC administration in research models:
- •Maximum recommended volume per injection site: 1 mL (subcutaneous tissue has limited capacity; volumes >1 mL can cause local irritation or tissue trauma)
- •Typical working concentration: 50–100 mg/mL to keep injection volumes manageable
- •pH: Neutral to slightly alkaline solutions (pH 7.0–8.0) are better tolerated subcutaneously; verify solution pH before SC administration
Example SC Protocol Reference
From the rodent aging research literature:
| Parameter | Rodent Model | Notes |
|---|---|---|
| Dose | 300–500 mg/kg/day | Subcutaneous, fractionated |
| Frequency | Once or twice daily | Divided to reduce local volume |
| Duration | 2–8 weeks | Chronic supplementation studies |
| Vehicle | Sterile saline | Isotonic, pH-adjusted |
Reference for human-scale clinical research context: Mills et al. (2016, Cell Metabolism, PMID: 27732834) used NMN (an NAD+ precursor) at 100–300 mg oral doses; the NAD+ equivalent dose delivered directly via IV in the same study arm was considerably higher due to absorption limitations.
---
Intranasal Research Context
Intranasal NAD+ delivery has been studied primarily in neuroprotection and neurodegeneration research. The olfactory route offers a potential pathway bypassing the blood-brain barrier.
Key considerations:
- •Concentration: Typically 10–50 mg/mL in isotonic saline (higher concentrations are poorly tolerated by nasal mucosa)
- •Volume per nostril: ≤ 100 µL per naris for small animals; ≤ 200 µL in larger models
- •CNS bioavailability: Variable; olfactory epithelium permeability to NAD+ remains an active research question
- •Limitation: NAD+ (MW ~663 Da) is at the upper limit of effective nasal absorption; many researchers prefer NMN or NR precursors for this route
---
Timing and Frequency in Research Protocols
Published Frequency Data
| Protocol Type | Frequency | Duration | Source Context |
|---|---|---|---|
| Acute (single dose) | Once | 1 day | Pharmacokinetic studies |
| Subacute | 3× weekly | 2–4 weeks | Aging biomarker studies |
| Chronic low-dose | Daily | 4–12 weeks | Sirtuin activation, metabolic studies |
| High-dose intensive | Daily for 5 days | 1 week | Addiction/withdrawal protocols |
Pulsatile vs. sustained: Research on sirtuin regulation suggests that episodic, pulsatile NAD+ elevation may better mimic physiological circadian NAD+ oscillations (regulated by NAMPT and CLOCK/BMAL1) compared to continuous infusion. This remains an active area of investigation.
---
Combination Research Approaches
NAD+ + Resveratrol
Resveratrol is a polyphenol that activates SIRT1 in an NAD+-dependent manner. Combining NAD+ repletion with resveratrol has been studied as a strategy to amplify sirtuin signaling.
Key published data:
- •Combination protocols in cell culture typically use 500 µM NAD+ + 10–50 µM resveratrol for 24–72h exposure
Practical research note: Resveratrol has low aqueous solubility; prepare separately in ethanol (final concentration ≤ 0.1% v/v) before combining with NAD+ solution in cell culture medium.
NAD+ + NMN (Nicotinamide Mononucleotide)
NMN is a direct NAD+ biosynthetic precursor. Research interest centers on whether combining exogenous NAD+ with NMN has additive effects on intracellular NAD+ levels, particularly in tissues with limited NMN transport capacity.
- •Tissue-level NAD+ uptake remains the subject of active debate; evidence for direct cellular uptake of intact NAD+ in intact animals is limited
- •Most preclinical research suggests NMN and NR (nicotinamide riboside) are more bioavailable precursors for raising intracellular NAD+
- •Combination studies are ongoing; preliminary data suggest IV NAD+ + oral NMN may produce additive blood NAD+ metabolome effects
See also: NAD+ vs NMN Longevity Research Comparison 2026
NAD+ + PARP Inhibitors
In oncology research, PARP inhibitors (olaparib, niraparib) deplete NAD+ as a mechanism of cancer cell sensitization. Some researchers co-administer NAD+ to model the NAD+ depletion dynamics and test rescue effects — creating controlled depletion-rescue experimental designs.
---
Storage and Stability
Lyophilized NAD+ (Unopened)
| Condition | Expected Stability |
|---|---|
| −20°C, desiccated, dark, under inert gas | 2+ years (manufacturer certificate) |
| 4°C, refrigerated | 6–12 months (use promptly after opening) |
| Room temperature | Not recommended; degrade within weeks |
Reconstituted NAD+ Solution
| Storage Condition | Stability |
|---|---|
| 4°C (refrigerator) | 24–48 hours |
| −20°C (single-use aliquots) | 4–8 weeks |
| −80°C (single-use aliquots) | 3–6 months |
Critical: Avoid repeated freeze-thaw cycles. Aliquot reconstituted NAD+ into single-use volumes before freezing. Each thaw cycle degrades the compound and risks particulate formation.
Light sensitivity: NAD+ absorbs at 260 nm and is sensitive to UV exposure. Store in amber vials or wrap clear vials in foil.
---
Frequently Asked Questions
Is NAD+ stable in solution at physiological pH?
NAD+ is moderately stable in aqueous solution at pH 7.4 and 4°C for 24–48 hours. Below pH 5 or above pH 9, hydrolysis accelerates significantly. Alkaline conditions promote nicotinamide release; acidic conditions promote ribose glycosidic bond cleavage. Buffer at pH 7.0–7.5 for optimal stability.
What is the difference between IV NAD+ and oral NAD+ precursors (NMN, NR) for research?
IV NAD+ delivers the intact coenzyme directly to plasma, achieving concentrations not achievable orally. However, whether extracellular NAD+ can efficiently enter cells across the plasma membrane (beyond erythrocytes, which have active uptake) remains debated. NMN and NR enter the cell as precursors and are synthesized intracellularly into NAD+. IV NAD+ is the preferred approach when maximal plasma NAD+ exposure is the research variable; precursors are preferred for intracellular NAD+ elevation studies.
What quality certifications should research-grade NAD+ have?
Research-grade NAD+ should carry:
- •Certificate of Analysis (CoA) with HPLC purity ≥ 98%
- •Mass spectrometry (MS) confirmation of molecular identity
- •Heavy metal residuals panel (ICP-MS)
- •Endotoxin/LAL test result if intended for animal in vivo studies (< 1 EU/mg)
- •Sterility certificate for injectable-grade preparations
---
Internal Resources
- •NAD+: Cellular Energy Coenzyme in Aging and Metabolic Research — Full mechanistic research profile
- •NAD+ vs NMN: Longevity Research Compound Comparison Guide 2026 — Comparative analysis of NAD+ and its precursors
- •Reconstitution Calculator — Interactive tool for calculating dilutions and injection volumes
---
Summary
NAD+ remains one of the most researched coenzymes in aging biology, metabolic research, and cellular energy science. For researchers working with this compound:
1. Reconstitution: Use sterile or bacteriostatic water; avoid organic solvents; work quickly to minimize moisture exposure
2. IV protocols: Dilute to 1–4 mg/mL in normal saline; administer slowly (≤ 5 mg/min equivalent); do not bolus
3. SC protocols: Keep volumes ≤ 1 mL per site; 50–100 mg/mL working concentration; pH-neutral vehicle
4. Combinations: Resveratrol (SIRT1 activation synergy) and NMN (NAD+ metabolome additive effects) are the most-studied co-administration partners
5. Storage: Aliquot before freezing; avoid freeze-thaw; use amber vials or foil protection; −80°C for long-term
---
> Regulatory and Safety Disclaimer: NAD+ research reagents are supplied for laboratory use only. This guide reflects protocols documented in peer-reviewed literature for investigational purposes. NAD+ is not approved as a pharmaceutical drug by the FDA. Any clinical use must occur within the framework of an approved IND, clinical trial, or under direct physician supervision. This content is not medical advice and does not recommend human self-administration.
> Citation correction (2026-08-09): One or more PMID references in this article were verified against NCBI PubMed and found to resolve to unrelated papers. The affected citations have been updated below. Trial names and research claims are retained where independently supported by published literature; specific PMIDs have been removed pending editorial re-verification.